Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. Two of six patients experienced dose-limiting neutropenia at a dose of paclitaxel 140 mg/m2/96 hours and cisplatin ...

Cancer Control at the District Hospital Level in Sub-Saharan Africa: An Educational and Resource Needs Assessment of General Practitioners A total of 109 patients were enrolled. The median number of ...

The objective of this phase II and pharmacologic study was to explore the feasibility, toxicity and activity of adaptive intrapatient dose escalation of cisplatin in a dose-intensive weekly schedule ...

The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma ...

Pedmark significantly reduces cisplatin-induced hearing loss in pediatric and AYA patients with non-metastatic solid tumors. The trial confirmed Pedmark's non-interference with cisplatin's antitumor ...